Dr. Burger on the Changing Treatment Landscape of CLL

Video

In Partnership With:

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Jan A. Burger, MD, PhD, tenured professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, lecturer, internal medicine, Albert-Ludwigs University, School of Medicine, Freiberg, Germany, faculty, Graduate School of Biomedical Sciences, University of Texas-Houston Health Science Center, discusses the changing treatment landscape of chronic lymphocytic leukemia (CLL).

The addition of multiple treatment options has provided a boost in treating CLL, since most patients are doing better than what was previously seen with chemoimmunotherapy, Burger explains. Additionally, patients are experiencing fewer toxicities with these different agents, Burger says.

Progress still needs to be made with new agents, Burger notes. Problems with toxicities and resistance can still arise, Burger continues. However, outcomes and life expectancy have improved for these patients, Burger concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine